行情

TNXP

TNXP

Tonix
NASDAQ

实时行情|Nasdaq Last Sale

0.6457
-0.0643
-9.06%
盘后: 0.6510 +0.0053 +0.82% 19:42 04/01 EDT
开盘
0.6815
昨收
0.7100
最高
0.7000
最低
0.6222
成交量
200.31万
成交额
--
52周最高
31.40
52周最低
0.3902
市值
3,186.73万
市盈率(TTM)
-0.0080
分时
5日
1月
3月
1年
5年

分析师评级

1位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

目标价格预测

分析师预测TNXP价格均价为2.500,最高价位2.500,最低价为2.500。

EPS

TNXP 新闻

更多
  • Tonix Pharmaceuticals EPS misses by $1.37
  • seekingalpha · 03/25 02:19
  • Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2019 Financial Results and Operational Highlights
  • GlobeNewswire · 03/24 22:15
  • Tonix Pharmaceuticals to Deliver Virtual Presentation for Spring Investor Summit
  • GlobeNewswire · 03/23 21:30
  • Profit-taking pressures Moderna after Hahn comments on vaccine timeline
  • seekingalpha · 03/19 22:00

所属板块

生物技术和医学研究
-4.52%
制药与医学研究
-2.91%

热门股票

代码
价格
涨跌幅

TNXP 简况

Tonix Pharmaceuticals Holding Corp. is a clinical-stage pharmaceutical company. The Company's drug development programs are directed toward disorders affecting the central nervous system (CNS), and include fibromyalgia (FM), and post-traumatic stress disorder (PTSD). It is focused on developing a portfolio of product candidates, including one product candidate in clinical development for registration in two indications. TNX-102 SL (cyclobenzaprine hydrochloric acid (HCl) sublingual tablets), is a disintegrating tablet containing cyclobenzaprine (CBP) for sublingual administration. The Company has completed Phase IIb BESTFIT trial of TNX-102 SL for fibromyalgia. It is being evaluated in the Phase III AFFIRM study for the treatment of fibromyalgia. The Company is also conducting AtEase trial, which is a Phase II clinical trial of TNX-102 SL in military-related PTSD. It also has a pipeline of other product candidates, including TNX-301, a fixed dose combination drug product (CDP).
展开

微牛提供Tonix Pharmaceuticals Holding Corp(NASDAQ-TNXP)的股票价格,实时市场报价,专业分析师评级,深度图表和免费的TNXP股票新闻,以帮助您做出投资决策。